MediciNova rises after positive data from mid-stage cancer treatment study

Medicinova

20/11/2023 12:34

** Shares of MediciNova's  MNOV.O  up 17.4% at $2.1
premarket
    ** Drug developer on Sunday reported positive results from
mid-stage trial of its experimental treatment, MN-166, against
Glioblastoma (GBM)
    ** GBM is a fast-growing and aggressive type of cancer that
occurs in the brain or spinal cord
    ** MN-166 and anti-cancer medication temozolomide's
combination treatment was safe and well-tolerated, and no
unexpected adverse effects were reported - company
    ** "At 6 months progression-free survival or how long before
the disease begins to worsen, for the combo-treatment was 44%
for new GBM and 31% for recurrent GBM", says co 
    ** As of last close, stock down 13.2% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))